Current financial headlines

Sharemaestro Newsreel

Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.

Showing
2485–2520
Headlines
4023
Sources here
11
Companies here
29
Current section United States Drug Manufacturers - Specialty & Generic news

Chronological news

Earlier headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Supernus Pharmaceuticals Inc (SUPN) Financial Health: Profitability & Balance Sheet Analysis

Supernus Pharmaceuticals Inc (SUPN) currently holds a financial score of 7.52, ranking 111th out of 155 in the Pharmaceuticals industry, indicating stable financial health and high operating efficiency. The company recently reported a quarterly revenue of $207.71 million, marking a 38.63% year-over-year increase, and …

SUPN main company
Sharemaestro market context Price below Trend Line 52 weeks +7.6% SUPN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Elanco Animal Health Incorporated $ELAN is Redwood Grove Capital LLC's Largest Position

Redwood Grove Capital LLC maintains Elanco Animal Health Incorporated ($ELAN) as its largest position, despite reducing its stake by 17% in the first quarter, holding 1.29 million shares valued at approximately $30.9 million. This represents about 10% of Redwood Grove Capital's portfolio. Institutional ownership …

ELAN main company
Sharemaestro market context Price below Trend Line 52 weeks +32.2% ELAN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Teva Pharmaceutical Industries (NYSE: TEVA) Q2 loss while raising brand outlook

Teva Pharmaceutical Industries reported a Q2 2026 GAAP net loss of $576 million but maintained its full-year revenue and free cash flow guidance, while raising the outlook for its key innovative brands (AUSTEDO, AJOVY, and UZEDY) to approximately $3.7 billion. The loss was primarily …

TEVA main company
Sharemaestro market context Trend signal active 52 weeks +99.2% · Next-week setup positive 56.3% TEVA stored weekly price path from 22 Aug 2025 to 14 Aug 2026

BIOA|BIOAGE Labs Inc|Price:21.950|Chg%:+1.070

This article provides a comprehensive stock analysis of BIOAGE Labs Inc (BIOA) by TradingKey, highlighting its strong fundamentals, high growth potential, and "Buy" rating from analysts with a target price of $42.88. The company is in a growing phase, has high profit growth, and …

BIOA main company
Sharemaestro market context Price below Trend Line 52 weeks +129.9% · Next-week setup positive 65.7% BIOA stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Evotec Number of Employees 2026 | Employee Count & Headcount Data

Evotec SE (XETRA: EVT) had approximately 4,535 employees worldwide as of March 2026, marking a 7.3% decline from 2023 but a 0.4% increase year-over-year in 2026. The company is actively hiring with 142 job postings in 2026. The workforce is concentrated in the UK, …

EVO main company
Sharemaestro market context Price below Trend Line 52 weeks -46.2% · Next-week setup negative 42.6% EVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026

AKBA|Akebia Therapeutics Inc|Price:1.275|Chg%:-0.005

Akebia Therapeutics Inc (AKBA) has a healthy fundamental outlook and high growth potential, with its valuation considered fairly valued. Despite strong analyst ratings with a "Strong Buy" consensus and a high institutional ownership, the stock is currently trading sideways. The company is a biopharmaceutical …

AKBA main company
Sharemaestro market context Price below Trend Line 52 weeks -72.6% AKBA stored weekly price path from 22 Aug 2025 to 14 Aug 2026

United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet

United Therapeutics announced that the ADVANCE OUTCOMES study of ralinepag for pulmonary arterial hypertension (PAH) has been published in The Lancet. The study, which included predominantly pre-treated patients, met its primary endpoint by reducing the risk of a clinical worsening event by 55% compared …

UTHR main company
Sharemaestro market context Trend signal ended 52 weeks +60.1% · Next-week setup positive 58.0% UTHR stored weekly price path from 22 Aug 2025 to 14 Aug 2026

How Collegium's Quarterly Beat but Softer Outlook Could Reframe Collegium Pharmaceutical (COLL) Investors

Collegium Pharmaceutical reported strong quarterly revenue and earnings that exceeded analyst estimates, but its full-year guidance was softer than expected. This divergence highlights investor focus on how the company's management views its medium-term growth and product momentum, especially given its concentrated portfolio in pain …

COLL main company
Sharemaestro market context Price below Trend Line 52 weeks -27.8% COLL stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Indivior PLC (INDV) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Indivior PLC (INDV), highlighting its strong valuation score of 9.73, which ranks it highly within the Pharmaceuticals industry. It details the company's current P/E ratio, its market capitalization, and stock performance, while noting that data for P/B, …

INDV main company
Sharemaestro market context Trend signal active 52 weeks +60.4% INDV stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Elanco Animal Health Incorporated (ELAN) Earnings Expected to Grow: Should You Buy?

Elanco Animal Health (ELAN) is expected to report a year-over-year increase in earnings and revenues for the quarter ended June 2026. The company has a Zacks Earnings ESP of +3.16% and a Zacks Rank #2 (Buy), suggesting a high probability of an earnings beat. …

ELAN main company
Sharemaestro market context Price below Trend Line 52 weeks +32.2% ELAN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Talphera, Inc. Revenue Breakdown – MUN:R5XA

Talphera, Inc. (MUN:R5XA) generated a total revenue of 23.84K EUR last year, a significant decrease from 589.81K EUR in the previous year. The "Innovative Therapies" segment was the primary revenue driver, accounting for all 23.84K EUR. The United States was the sole geographical contributor …

TLPH main company
Sharemaestro market context Trend signal active 52 weeks +149.6% · Next-week setup negative 38.8% TLPH stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Evolus Inc (EOLS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Evolus Inc (EOLS), detailing its price movement, support and resistance levels, and insights from various technical indicators and moving averages. The stock currently has a price momentum score of 4.73 and is trading between a resistance of …

EOLS main company
Sharemaestro market context Trend signal active 52 weeks +6.2% EOLS stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Evolus Inc (EOLS) Institutional Confidence

The article provides an overview of Evolus Inc's institutional confidence, detailing its current score, industry ranking, and institutional shareholding proportion, which has decreased by 14.84% quarter-over-quarter. It lists key institutional shareholders and their recent activity. The institutional shareholding score for EOLS is 7.00, placing …

EOLS main company
Sharemaestro market context Trend signal active 52 weeks +6.2% EOLS stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Cumberland Pharmaceuticals Inc (CPIX) Institutional Confidence

The article provides an institutional confidence score for Cumberland Pharmaceuticals Inc (CPIX), which currently stands at 3.00, ranking 92 out of 155 in the Pharmaceuticals industry. It highlights that the institutional shareholding proportion is 19.66%, a 30.06% decrease quarter-over-quarter. James Simons is identified as …

CPIX main company
Sharemaestro market context Trend signal active 52 weeks +136.8% CPIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Amphastar Sets Aug. 6 Webcast for Second-Quarter Results

Amphastar Pharmaceuticals (NASDAQ: AMPH) announced it will release its second-quarter 2026 financial results on Thursday, August 6, 2026, after the market closes. The company will also host a conference call at 2:00 p.m. Pacific Time to discuss the results, with access available via dial-in …

AMPH main company
Sharemaestro market context Price below Trend Line 52 weeks -31.4% AMPH stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Kamada Ltd (KMDA) Financial Health: Profitability & Balance Sheet Analysis

Kamada Ltd (KMDA) has a stable financial score of 7.95, ranking 90th in the Pharmaceuticals industry, indicating high operating efficiency. The company recently reported a 2.78% year-over-year increase in quarterly revenue to $45.24 million and a 4.24% rise in net profit. However, specific detailed …

KMDA main company
Sharemaestro market context Price below Trend Line 52 weeks +8.8% KMDA stored weekly price path from 22 Aug 2025 to 14 Aug 2026

AYTU|Aytu Biopharma Inc|Price:2.135|Chg%:+0.075

This article provides a detailed financial overview of Aytu Biopharma Inc. (AYTU), including its latest earnings report from May 13, 2026, and historical quarterly and annual financial indicators. It covers key metrics such as EPS, revenue, net profit, margins, debt-to-assets ratio, and various balance …

AYTU main company
Sharemaestro market context Price below Trend Line 52 weeks +8.2% · Next-week setup negative 37.8% AYTU stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Cronos Group Inc (CRON) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Cronos Group Inc (CRON), indicating a current earnings forecast score of 7.00, ranking 112 out of 155 in the Pharmaceuticals industry. Based on 2 analysts, the stock has an average price target of $2.90 and a "Buy" …

CRON main company
Sharemaestro market context Trend signal active 52 weeks +20.8% CRON stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Talphera Inc (TLPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Talphera Inc (TLPH), detailing its current price momentum, support and resistance levels, and signals from various technical indicators and moving averages. The stock currently ranks 17th in the Pharmaceuticals industry for price momentum, and its price is …

TLPH main company
Sharemaestro market context Trend signal active 52 weeks +149.6% · Next-week setup negative 38.8% TLPH stored weekly price path from 22 Aug 2025 to 14 Aug 2026

SIGA Technologies Inc Today's Market Trends | SIGA Stock Real-Time Quotes, Trading Strategies & Related Analysis | TradingKey

This article provides an in-depth analysis of SIGA Technologies Inc. (SIGA) stock, including real-time quotes, market trends, key financials, and trading strategies. It highlights the company's strong fundamentals and growth potential, despite recent stock market performance, and details its flagship product, TPOXX, an antiviral …

SIGA main company
Sharemaestro market context Price below Trend Line 52 weeks -62.8% SIGA stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Phibro Animal declares $0.12 dividend

* Phibro Animal (PAHC [https://seekingalpha.com/symbol/PAHC]) declares $0.12/share quarterly dividend [https://seekingalpha.com/pr/20598416-phibro-animal-health-corporation-declares-quarterly-dividend]. * Forward yield [https://seekingalpha.com/symbol/PAHC/dividends/yield?source=news_bullet] 1.32% * Payable Sept. 23; for shareholders of record Sept. 2; ex-div Sept. 2. * See PAHC Dividend Scorecard, Yield Chart, & Dividend Growth. [https://seekingalpha.com/symbol/PAHC/dividends?source=news_bullet] MORE ON PHIBRO ANIMAL * …

PAHC main company
Sharemaestro market context Price below Trend Line 52 weeks +7.1% PAHC stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Perrigo Company PLC (PRGO) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Perrigo Company PLC (PRGO), noting its current valuation score is 8.65, ranking 75th in the Pharmaceuticals industry. The article highlights the company's current P/E ratio and mentions that relevant data for P/B, P/S, and P/CF ratios have …

PRGO main company
Sharemaestro market context Price above Trend Line 52 weeks -42.2% PRGO stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Cronos Group Inc Revenue Breakdown – GETTEX:7CI

Cronos Group Inc. (7CI) generated €124.81 million in revenue last year, with its Cannabis Flower segment being the main contributor at €93.98 million. The majority of this revenue, €78.25 million, came from the Canadian market. This highlights the company's reliance on its cannabis flower …

CRON main company
Sharemaestro market context Trend signal active 52 weeks +20.8% CRON stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Emergent BioSolutions Inc (EBS) Institutional Confidence

Emergent BioSolutions Inc (EBS) has an institutional shareholding score of 7.00, placing it 50th out of 155 in the Pharmaceuticals industry. The institutional shareholding proportion is 81.98%, a slight decrease quarter-over-quarter. James Simons is the largest institutional shareholder, with other significant holders including BlackRock …

EBS main company
Sharemaestro market context Price below Trend Line 52 weeks -50.3% · Next-week setup negative 43.4% EBS stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership reduced its stake in Kiniksa Pharmaceuticals International (NASDAQ:KNSA) by 16.4% in the first quarter, selling 175,550 shares and retaining 892,666 shares valued at $42,982,000. Other institutional investors also adjusted their holdings, while company insiders, including a CEO and an insider, …

KNSA main company
Sharemaestro market context Trend signal active 52 weeks +127.4% · Next-week setup positive 55.5% KNSA stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Perrigo to Present at the Canaccord 46th Annual Growth Conference

Perrigo Company plc announced that Interim President and CEO Albert Manzone and CFO Eduardo Bezerra will present at the Canaccord 46th Annual Growth Conference on August 12th at 10:30 AM EDT. The presentation will be webcast live on the company's investor relations website. Perrigo, …

PRGO main company
Sharemaestro market context Price above Trend Line 52 weeks -42.2% PRGO stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Hims & Hers Tokenized Stock price today, HIMSx to USD chart, marketcap and volume

This article provides current information on Hims & Hers Tokenized Stock (HIMSx), including its price, market cap, trading volume, and a detailed chart. HIMSx is a blockchain-based tokenized representation of Hims & Hers Health, Inc. Class A common stock, issued through Backed Finance's xStocks …

HIMS main company
Sharemaestro market context Trend signal active 52 weeks -36.8% HIMS stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Tilray projects $68M-$75M adjusted EBITDA in fiscal 2027 as it targets margin expansion

Earnings Call Insights: Tilray Brands, Inc. (TLRY) Q4 fiscal 2026 MANAGEMENT VIEW * "Fiscal 2026 proves something important and exciting. Tilray Brands is more than the company many people think it is." (President, CEO & Chairman Irwin Simon) "Today, Tilray is a diversified global …

TLRY main company
Sharemaestro market context Price below Trend Line 52 weeks -59.4% · Next-week setup negative 41.4% TLRY stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Liquidia Corp (LQDA) Valuation: PE, PB & Fair Value Analysis

Liquidia Corp (LQDA) currently holds a valuation score of 6.12, placing it 146th out of 155 companies in the Pharmaceuticals industry. Its P/E ratio is 346.96, which is slightly below its recent high and significantly above its recent low. The company has not yet …

LQDA main company
Sharemaestro market context Trend signal active 52 weeks +177.3% · Next-week setup positive 56.2% LQDA stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Lifecore Biomedical Inc (LFCR) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Lifecore Biomedical Inc (LFCR), a company within the Pharmaceuticals industry. It highlights that LFCR has a risk assessment score of 4.90, ranking 78 out of 155 in its industry, and a beta value of 1.07. The report …

LFCR main company
Sharemaestro market context Price below Trend Line 52 weeks -37.9% LFCR stored weekly price path from 22 Aug 2025 to 14 Aug 2026

INDV|Indivior PLC|Price:40.970|Chg%:+0.940

This article provides a comprehensive stock analysis of Indivior PLC (INDV) by TradingKey, highlighting its strong fundamentals, high growth potential, and "fairly valued" status within the Pharmaceuticals industry. The analysis details Indivior's score, key insights, and an overview of its product portfolio for substance-use …

INDV main company
Sharemaestro market context Trend signal active 52 weeks +60.4% INDV stored weekly price path from 22 Aug 2025 to 14 Aug 2026

LNTH|Lantheus Holdings Inc|Price:102.540|Chg%:-5.490

This article provides a comprehensive stock analysis of Lantheus Holdings Inc (LNTH) by TradingKey, highlighting its strong fundamentals, high growth potential, and fair valuation within the Healthcare Equipment & Supplies industry. Despite recent weak market performance, the company exhibits robust fundamentals and is considered …

LNTH main company
Sharemaestro market context Trend signal active 52 weeks +73.4% LNTH stored weekly price path from 22 Aug 2025 to 14 Aug 2026

ANIP|ANI Pharmaceuticals Inc|Price:79.255|Chg%:-1.175

This article provides a comprehensive stock analysis of ANI Pharmaceuticals Inc (ANIP) by TradingKey. It highlights the company's healthy fundamentals, high growth potential, and fair valuation within the pharmaceuticals industry. The analysis also covers institutional ownership, analyst ratings, and a detailed breakdown of how …

ANIP main company
Sharemaestro market context Price below Trend Line 52 weeks -15.9% ANIP stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Amylyx Pharmaceuticals Inc (AMLX) Institutional Confidence

Amylyx Pharmaceuticals Inc (AMLX) has an institutional shareholding score of 10.00, placing it at the top of the Biotechnology & Medical Research industry. Institutional shareholding proportion increased by 5.01% quarter-over-quarter, reaching 104.12%. Fidelity Management & Research Company LLC is a significant institutional shareholder, increasing …

AMLX main company
Sharemaestro market context Trend signal active 52 weeks +132.6% · Next-week setup positive 55.7% AMLX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Aquestive Therapeutics Inc (AQST) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Aquestive Therapeutics Inc (AQST), highlighting its current price momentum score, support and resistance levels, and indicator readings. It details various technical indicators like MACD, RSI, and moving averages, offering "Sell", "Neutral", and "Buy" signals. The analysis suggests …

AQST main company
Sharemaestro market context Price above Trend Line 52 weeks +6.8% AQST stored weekly price path from 22 Aug 2025 to 14 Aug 2026

ANI Pharmaceuticals, Inc. $ANIP Shares Purchased by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership significantly increased its stake in ANI Pharmaceuticals (ANIP) by 19.3% in the first quarter, now owning 2.52% of the company's shares. This comes as ANI Pharmaceuticals reported strong quarterly results, exceeding EPS and revenue consensus estimates, and provided positive fiscal …

ANIP main company
Sharemaestro market context Price below Trend Line 52 weeks -15.9% ANIP stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context